Novo Nordisk, the Danish pharmaceuticals company, is launching FlexPen, its new insulin pen this week in Europe and then the U.S.

The pen is expected to be the most popular product of its type worldwide within a short period of time, replacing NovoLet, Novo Nordisk's product which is currently the most used worldwide. It has cost Novo Nordisk a nine digit sum to develop FlexPen and Danish diabetics have given their opinions as to how the pen ought to function and look in two trials.

Enhanced safety features
FlexPen® provides confidence in managing insulin injection for both healthcare professionals and people with diabetes

Enhanced simplicity
Very easy to learn – significantly more people taking insulin believed that it was very easy to learn how to use FlexPen®¹

Discreetness
Significantly more people taking insulin believed that FlexPen® is suitable for use in public.¹

Preferred by people with diabetes
In a comparative handling study¹, 82% of people with diabetes preferred FlexPen®

FlexPen ® - delivers insulin and confidence
Fewer and simpler steps lead to greater confidence in handling insulin injection, which may lead to improved  compliance with therapy¹

• Confident dose setting -large, clear scale for confident dose setting and precise dose adjustment
• Confident dose delivery - dose scale returns to zero during injection to allow visual confirmation of dose delivery. Impossible to dial a dose larger than remains in the pen
• Simple, single-step dose setting
      Dose setting in 1 unit increments up to a maximum 60 units per injection 
      Dose correction is easy – simply dial back to the correct dose. 
      The dose scale returns to zero during injection so FlexPen® is always ready to use

Reference 1
Lawton S, Berg B. Comparative evaluation of FlexPen ® , a new prefilled insulin delivery system, among patients and healthcare professionals. Diabetes 2001; 50 (Suppl 2): A440. 

View The "New Product" Archives